Kent D Heyborne1, Amanda A Allshouse2, J Christopher Carey3. 1. Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO; Department of Obstetrics and Gynecology, University of Colorado Denver, Denver, CO. Electronic address: kent.heyborne@dhha.org. 2. University of Colorado School of Public Health, Aurora, CO. 3. Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO; Department of Obstetrics and Gynecology, University of Colorado Denver, Denver, CO.
Abstract
OBJECTIVE: We sought to determine if maternal weight or body mass index (BMI) modifies the effectiveness of 17-alpha hydroxyprogesterone caproate (17OHP-C). STUDY DESIGN: We performed a secondary analysis of the Maternal-Fetal Medicine Units Network Trial for the Prevention of Recurrent Preterm Delivery by 17-Alpha Hydroxyprogesterone Caproate. Binomial regression models were estimated to determine the relative risk (RR) of preterm birth (PTB) in women randomized to 17OHP-C vs placebo according to BMI category and maternal weight. Adjusted models considered inclusion of potential confounders. RESULTS: In all, 443 women with complete data were included. 17OHP-C is effective in preventing PTB <37 weeks only in women with prepregnancy BMI <30 kg/m(2) (RR, 0.54; 95% confidence interval, 0.43-0.68). Above this BMI threshold there is a nonsignificant trend toward an increased risk of PTB (RR, 1.55; 95% confidence interval, 0.83-2.89) with 17OHP-C treatment. When analyzing by maternal weight, a similar threshold is observed at 165 lb, above which 17OHP-C is no longer effective. CONCLUSION: The effectiveness of 17OHP-C is modified by maternal weight and BMI, and treatment does not appear to reduce the rate of PTB in women who are obese or have a weight >165 lb. This finding may be due to subtherapeutic serum levels in women with increased BMI or weight. Studies of adjusted-dose 17OHP-C in women who are obese or who weigh >165 lb are warranted, and current recommendations regarding the uniform use of 17OHP-C regardless of maternal BMI and weight may deserve reassessment.
RCT Entities:
OBJECTIVE: We sought to determine if maternal weight or body mass index (BMI) modifies the effectiveness of 17-alpha hydroxyprogesterone caproate (17OHP-C). STUDY DESIGN: We performed a secondary analysis of the Maternal-Fetal Medicine Units Network Trial for the Prevention of Recurrent Preterm Delivery by 17-Alpha Hydroxyprogesterone Caproate. Binomial regression models were estimated to determine the relative risk (RR) of preterm birth (PTB) in women randomized to 17OHP-C vs placebo according to BMI category and maternal weight. Adjusted models considered inclusion of potential confounders. RESULTS: In all, 443 women with complete data were included. 17OHP-C is effective in preventing PTB <37 weeks only in women with prepregnancy BMI <30 kg/m(2) (RR, 0.54; 95% confidence interval, 0.43-0.68). Above this BMI threshold there is a nonsignificant trend toward an increased risk of PTB (RR, 1.55; 95% confidence interval, 0.83-2.89) with 17OHP-C treatment. When analyzing by maternal weight, a similar threshold is observed at 165 lb, above which 17OHP-C is no longer effective. CONCLUSION: The effectiveness of 17OHP-C is modified by maternal weight and BMI, and treatment does not appear to reduce the rate of PTB in women who are obese or have a weight >165 lb. This finding may be due to subtherapeutic serum levels in women with increased BMI or weight. Studies of adjusted-dose 17OHP-C in women who are obese or who weigh >165 lb are warranted, and current recommendations regarding the uniform use of 17OHP-C regardless of maternal BMI and weight may deserve reassessment.
Authors: Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin Journal: Am J Obstet Gynecol Date: 2013-10-07 Impact factor: 8.661
Authors: Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper Journal: Am J Obstet Gynecol Date: 2011-03-22 Impact factor: 8.661
Authors: Vineta Fellman; Lena Hellström-Westas; Mikael Norman; Magnus Westgren; Karin Källén; Hugo Lagercrantz; Karel Marsál; Fredrik Serenius; Margareta Wennergren Journal: JAMA Date: 2009-06-03 Impact factor: 56.272
Authors: Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Ebony B Carter; Alison G Cahill; Margaret A Olsen; George A Macones; Methodius G Tuuli; Molly J Stout Journal: J Perinatol Date: 2019-06-19 Impact factor: 2.521
Authors: Rupsa C Boelig; Luigi Della Corte; Sherif Ashoush; David McKenna; Gabriele Saccone; Shalini Rajaram; Vincenzo Berghella Journal: Am J Obstet Gynecol MFM Date: 2019-03-27
Authors: Kim A Boggess; Jeffrey B Baker; Amy P Murtha; Alan M Peaceman; Dinesh M Shah; Sylvia L Siegfried; Robert Birch Journal: AJP Rep Date: 2018-05-14